Related Experiment Video
Updated: Oct 3, 2025
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.0K
[Tardive neuroleptic-induced dyskinesias]
D V Zakharov1, Iu V Buriak1, V A Mihailov1
1Bekhterev National Medical Research Centerfor Psychiatry and Neurology, St. Petersburg, Russia.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|February 17, 2022
Summary
Tardive dyskinesia, a side effect of psychiatric drugs, causes involuntary movements. Normokinesin (tetrabenazine) shows promise in reducing these hyperkinetic movements by modulating brain neuron dopamine stimulation.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Drugs blocking dopaminergic transmission are crucial for psychiatric disease treatment.
- Tardive dyskinesia is a common, debilitating complication of long-term antipsychotic therapy.
- This extrapyramidal disorder involves involuntary facial and tongue hyperkinesis, impairing daily life.
Purpose of the Study:
- To review current treatment strategies for tardive dyskinesia.
- To evaluate Normokinesin (tetrabenazine) as a therapeutic option for tardive dyskinesia.
Main Methods:
- Literature review of existing tardive dyskinesia treatments.
- Analysis of Normokinesin's mechanism of action in reducing dopaminergic stimulation.
Main Results:
- Tardive dyskinesia significantly reduces patient quality of life.
- Normokinesin (tetrabenazine) effectively reduces hyperkinesis.
- The drug works by decreasing dopaminergic stimulation in brain neurons.
Conclusions:
- Normokinesin (tetrabenazine) represents a promising therapeutic approach for tardive dyskinesia.
- Modulating dopaminergic pathways offers a viable strategy for managing antipsychotic-induced hyperkinesis.
More Related Videos
Related Concept Videos
01:24Parkinson's Disease: Treatment
423
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
423
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
423
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
423
01:15Parkinson's Disease: Overview
797
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
797
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
710
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
710
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
513
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
513
01:15REM Sleep Behavior Disorder
456
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
456